RxDoctor Payments Data

Mrinalini Krishnan, MD

Advanced Heart Failure and Transplant Cardiology · Washington, DCNPI 1255686978

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,925 of the $111,197 with a category attached, or 62.0%. Actelion Pharmaceuticals US, Inc. accounts for 84.8% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $41,584, more than ten times the $3,188 reported in 2019.

$111,197in general payments, 2019–2025

Across 245 payments — averaging $453.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$94K
  • United Therapeutics Corporation$10K
  • Abbott$4K
  • Medtronic$1K
  • Abiomed$955
  • Bayer$362
  • plus $531 from 7 others

What the payments were for

  • Consulting fees$22,19020%
  • Speaking & faculty fees$68,92562%
  • Travel & lodging$10,58510%
  • Food & beverage$9,0958%
  • Education$4020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$87,682
Medicare patients
200
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag214$4,915,731
OpsumitMacitentan299$3,939,283
AdempasRiociguat129$1,732,160
Orenitram ErTreprostinil Diolamine86$1,094,127
Tyvaso DpiTreprostinil29$897,673
Ambrisentan65$291,324
WinrevairSotatercept-Csrk17$243,595
Tadalafil244$234,182
OpsynviMacitentan/Tadalafil17$220,498
AdcircaTadalafil18$116,817
EntrestoSacubitril/Valsartan44$60,251
JardianceEmpagliflozin59$58,377
EliquisApixaban41$43,014
Sildenafil Citrate29$35,545
Spironolactone113$1,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi$94,339$9,075,513530 claims
BayerAdempas$362$1,732,160129 claims
MerckWinrevair$195$243,59517 claims
United Therapeutics CorporationAdcirca$10,183$116,81718 claims
NovartisEntresto$18$60,25144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →